Dr. Bazhenova On The Pacific Trial With Durvalumab In Nsclc

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

PACIFIC-R: real-word durvalumab after chemo-RT in stage 3 NSCLC

Dr. Bazhenova on Ongoing Clinical Trials With Immunotherapy in NSCLC

Refining which patients benefit from consolidation durvalumab for stage III unresectable NSCLC

PACIFIC 6: durvalumab after sCRT in patients with NSCLC

Stage III NSCLC: When to Start Durvalumab

Dr. Spigel on the Rationale Behind the PACIFIC Trial

Dr. Simon on Durvalumab for Patients With Lung Cancer

PACIFIC trial updates: durvalumab after chemotherapy in NSCLC

Reactions to the PACIFIC Trial in Stage III NSCLC

PACIFIC trial of durvalumab for stage III NSCLC

PACIFIC Trial: Durvalumab for Stage 3 NSCLC

Durvalumab: the new standard of care for NSCLC?

Durvalumab Consolidation in NSCLC: The PACIFIC Trial

Targeted Oncology

Dr. Schwartz on the Results of the PACIFIC Trial

Dr. Feldman on Durvalumab for Patients With Lung Cancer

Durvalumab improves PFS in stage III lung cancer

How can durvalumab be used in NSCLC?

Phase III real-world PACIFIC-R trial for NSCLC